Caterina Casari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6353687/publications.pdf

Version: 2024-02-01

36	871	430874	477307
papers	citations	18 h-index	29 g-index

36	36	36	1246
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RASA3 is a critical inhibitor of RAP1-dependent platelet activation. Journal of Clinical Investigation, 2015, 125, 1419-1432.	8.2	113
2	Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood, 2012, 119, 2126-2134.	1.4	99
3	Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica, 2012, 97, 1855-1863.	3.5	70
4	Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2Bâ€“associated thrombocytopenia. Blood, 2013, 122, 2893-2902.	1.4	68
5	von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin Î±IIbÎ²3. Journal of Clinical Investigation, 2013, 123, 5071-5081.	8.2	42
6	von Willebrand Factor and Management of Heart Valve Disease. Journal of the American College of Cardiology, 2019, 73, 1078-1088.	2.8	37
7	Deletion of the Arp2/3 complex in megakaryocytes leads to microthrombocytopenia in mice. Blood Advances, 2017, 1, 1398-1408.	5.2	33
8	In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor. PLoS ONE, 2012, 7, e37508.	2.5	33
9	Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor. Haematologica, 2018, 103, 728-737.	3.5	32
10	A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood, 2020, 136, 740-748.	1.4	32
11	Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood, 2013, 121, 2135-2143.	1.4	25
12	The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. Blood, 2010, 116, 5371-5376.	1.4	23
13	LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight, 2016, 1, e88643.	5.0	23
14	CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 792-799.	2.4	20
15	Acquired platelet disorders. Thrombosis Research, 2016, 141, S73-S75.	1.7	20
16	Singleâ€domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine, 2020, 12, e11298.	6.9	20
17	Terminal Platelet Production is Regulated by Von Willebrand Factor. PLoS ONE, 2013, 8, e63810.	2.5	20
18	A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation. Scientific Reports, 2016, 6, 26306.	3.3	19

#	Article	IF	Citations
19	A factor VIIIâ€“nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. Blood, 2018, 132, 1193-1197.	1.4	19
20	Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1843-1858.	2.4	19
21	A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood, 2012, 120, 2723-2732.	1.4	16
22	A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization. Lab on A Chip, 2021, 21, 4791-4804.	6.0	14
23	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Therapy, 2023, 30, 245-254.	4.5	11
24	Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient. Haematologica, 2021, 106, 2287-2290.	3.5	10
25	Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets. Blood Advances, 2018, 2, 1417-1428.	5.2	9
26	Camelidâ€derived singleâ€chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1087-1110.	2.3	8
27	Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. Blood, 2014, 123, 3344-3353.	1.4	6
28	Rasa3 deficiency minimally affects thrombopoiesis but promotes severe thrombocytopenia due to integrin-dependent platelet clearance. JCI Insight, 2022, 7, .	5.0	6
29	Towards novel treatment options in von Willebrand disease. Haemophilia, 2022, 28, 5-10.	2.1	6
30	A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. Thrombosis and Haemostasis, 2019, 119, 1981-1993.	3.4	5
31	In vivo modulation of a dominantâ€negative variant in mouse models of von Willebrand disease type 2A. Journal of Thrombosis and Haemostasis, 2021, 19, 139-146.	3.8	5
32	Functional genetics. Thrombosis Research, 2012, 129, 336-340.	1.7	3
33	VON WILLEBRAND FACTOR ABNORMALITIES STUDIED IN THE MOUSE MODEL: WHAT WE LEARNED ABOUT VWF FUNCTIONS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013047.	1.3	3
34	Impact of the COVIDâ€19 pandemic on education and clinical training. Journal of Thrombosis and Haemostasis, 2021, 19, 2099-2100.	3.8	1
35	Identification of von Willebrand factor D4 domain mutations in patients of Afroâ€Caribbean descent: In vitro characterization. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12737.	2.3	1
36	A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient. Therapeutic Advances in Hematology, 2022, 13, 204062072210768.	2.5	0